Novartis
Novartis to close UK research site
March 16, 2011Research and Development Horsham, Novartis, job cuts, pharma job cuts
[UPDATE: Novartis has confirmed it will close its manufacturing site in Horsham, but continue to conduct respiratory research at the site …
Novartis’ COPD drug recommended for FDA approval
March 10, 2011Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …
Digital Pharma: online campaign directory updated
March 4, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra
The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Pharma-NHS diabetes project begins
February 9, 2011Sales and Marketing AstraZeneca, Lilly UK, MSD, NHS, Nottingham, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, joint working
A joint venture between the NHS, charities and the pharma sector has begun in Nottingham to help treat the city’s …
Novartis posts strong growth but warns of tough year ahead
January 27, 2011Sales and Marketing 2010 pharma results, Novartis
Novartis has posted strong sales growth for the full year but its chief executive warns of ‘headwinds in 2011’ as …
Bio and clinical plants feature in 2011 FOYA honours
January 25, 2011Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing
Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …
Novartis MS drug steals march over Merck rival
January 24, 2011Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis
Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
Novartis offers $470m to boost personalised cancer treatment
January 24, 2011Research and Development, Sales and Marketing Cancer, Genoptix, Novartis, cancer diagnostics, personalised medicine
Novartis has offered $470 million for a California-based laboratory whose diagnostic services it hopes will enhance personalised treatment. Genoptix specialises …
Novartis challenges Roche with MabThera biosimilar
January 11, 2011Research and Development Lonza MabThera, Novartis, Roche, Teva, biosimilar, rituximab
Novartis’ generics unit Sandoz has begun mid-stage trials of a biosimilar version of Roche’s blockbuster drug MabThera. The phase II …
Digital Pharma: First big pharma Android apps launched
January 4, 2011Medical Communications Android, Digital Pharma blog, Novartis, Sanofi-Aventis, apps, ipad, iphone
Big pharma’s smartphone marketing is starting to look beyond Apple’s attention-grabbing iPhone as companies produce the first apps for its …
Novartis adds R&D unit to new vaccines plant
December 31, 2010Manufacturing and Production, Research and Development Novartis, pharma manufacturing, vaccines
Swiss drugmaker Novartis is planning to spend $36 million to set up an R&D laboratory on the site of its …
Novartis submits meningococcal vaccine Bexsero for European approval
December 23, 2010Sales and Marketing Bexsero, MenB, Novartis, Vaccine, bacterial meningitis, bloodstream infection sepsis, meningococcal disease, meningococcal vaccine
Novartis has submitted its meningococcal vaccine Bexsero to European regulators for marketing approval. If approved the drug will be the …
Novartis blood cancer drug impresses in late stage trial
December 22, 2010Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug
Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …
Novartis makes $500m investment in Russia
December 21, 2010Manufacturing and Production, Research and Development Novartis, Russia, pharma manufacturing
Novartis is planning to invest $500 million in Russia over the next five years, in a programme which will include …
Latest content
FibroFind appoints Lee Borthwick as CEO
